Video
Dr. Min Dong discusses next steps with therapeutic toxins for urologic disease
Author(s):
“We are not just changing toxins for the sake of changing toxins; we are changing toxins to satisfy the needs from the clinical community,” says Min Dong, MD.
Video Player is loading.
In this video, Min Dong, MD,summarizes the main points of his talk, “New frontiers in therapeutic toxins for urologic disease,” which was presented at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction 2022 Winter Meeting. Dong is an associate professor of Urology at Harvard Medical School in Cambridge, Massachusetts.
Related Videos
Roger Dmochowski, MD, on real-world persistence with vibegron for OAB
Considerations for patient follow-up after onabotA administration
Administering onabotA: Improving patient comfort and easing anxiety
Experts discuss expanding use of vibegron for OAB
Ekene Enemchukwu, MD, on guideline-associated trends in OAB therapy use
Karyn S. Eilber, MD, on patient counseling for onabotA treatment for OAB
Optimizing onabotA for OAB: What are some common misconceptions?
Investigators characterize vibegron prescribing patterns for OAB
Expert outlines advantages of batteryless sacral neuromodulation device
Emmanuel Chartier-Kastler, MD, shares initial data on UroActive System in women with SUI
Related Content
